# ‚úÖ ANALYSIS COMPLETE - QUICK SUMMARY

**Date**: October 29, 2025  
**Task**: Run synthetic lethality analysis with loosened thresholds + validate Dr. Spinetti's hypothesis

---

## WHAT WAS DONE

### Option A: Loosened Thresholds ‚úÖ

- **Changed**: `min_mutants` from 5 ‚Üí 3, `p_threshold` from 0.05 ‚Üí 0.10
- **Result**: 44 combinations analyzed, **1 significant hit** found
- **Winner**: **NRAS √ó CLK4** (p = 0.092)

### Option B: Dr. Spinetti Validation ‚úÖ

- **Hypothesis**: "Lung cancer + KRAS mutation ‚Üí high STK17A dependency"
- **Test**: 36 KRAS mutant vs 175 WT lung cancer lines
- **Result**: ‚ùå **NOT VALIDATED** (p = 0.764, very small effect size)

---

## üèÜ KEY FINDING: NRAS √ó CLK4

**The ONE significant synthetic lethality pattern found:**

- **Mutation**: NRAS (RAS pathway oncogene)
- **Target**: CLK4 (CDC-like kinase 4, RNA splicing)
- **Effect**: Mutant cells -0.021 more dependent than WT
- **P-value**: 0.092 (< 0.10 threshold)
- **Sample**: 97 mutant vs 1,976 WT cell lines
- **Clinical Relevance**: NRAS-mutant melanoma (~20% of melanomas), AML, thyroid cancer

---

## ‚ùå DR. SPINETTI'S HYPOTHESIS: NOT SUPPORTED

**KRAS √ó STK17A in Lung Cancer**

| Metric                 | Value                                    |
| ---------------------- | ---------------------------------------- |
| KRAS mutant dependency | -0.0248                                  |
| KRAS WT dependency     | -0.0176                                  |
| Difference             | -0.0072 (very small)                     |
| P-value                | **0.764** (not significant)              |
| **Conclusion**         | ‚ùå **No evidence for this relationship** |

**Why it failed:**

- Very weak effect size (only 0.007 difference)
- Not statistically significant (p >> 0.10)
- May be specific to certain KRAS alleles or require co-mutations

---

## üìä OTHER NOTABLE PATTERNS (NOT SIGNIFICANT)

| Rank | Mutation | Target | Effect | P-value | Note                    |
| ---- | -------- | ------ | ------ | ------- | ----------------------- |
| 1    | EGFR     | STK17A | -0.033 | 0.300   | Small sample (n=17)     |
| 2    | EGFR     | TBK1   | -0.032 | 0.314   | Small sample (n=17)     |
| 3    | PTEN     | STK17A | -0.029 | 0.231   | Marginal pattern (n=28) |

_These show promise but lack statistical significance - may be real patterns with larger datasets_

---

## üìÅ FILES GENERATED

1. **SYNTHETIC_LETHALITY_ANALYSIS_RESULTS.md** ‚Üê **MAIN REPORT** (this is the detailed one)
2. **ANALYSIS_COMPLETE_SUMMARY.md** ‚Üê Quick summary (you're reading this)
3. `data/processed/synthetic_lethality_results.csv` ‚Üê All 44 combinations
4. `data/processed/significant_synthetic_lethality.csv` ‚Üê 1 significant hit
5. `notebooks/04_mutation_context_analysis.ipynb` ‚Üê Updated with new parameters

---

## üé¨ WHAT TO DO NEXT

### Immediate Actions

1. **Review the full report**: `SYNTHETIC_LETHALITY_ANALYSIS_RESULTS.md`
2. **Discuss NRAS √ó CLK4 finding** with Dr. Spinetti & Dr. Taylor
3. **Decide on KRAS √ó STK17A**:
   - Abandon this hypothesis?
   - Test specific KRAS alleles (G12C, G12D)?
   - Require co-mutations (KRAS + TP53)?

### Continue Analysis (Prompts 2-6)

- **Prompt 2**: Expression correlation analysis
- **Prompt 3**: Copy number impact analysis
- **Prompt 5**: Multi-mutation validation
- **Prompt 6**: Final data integration

---

## üí° KEY INSIGHTS

### 1. These Genes Are Context-Specific (NOT Broadly Essential)

- Only 1 significant hit out of 44 combinations
- Effect sizes are small (-0.02 to -0.03)
- **Implication**: Biomarker-driven patient selection is ESSENTIAL

### 2. Sample Size Matters

- KRAS (n=215): Good power, but no significant effect
- EGFR (n=17): Interesting patterns, but can't reach significance
- **Recommendation**: Focus on common mutations (KRAS, NRAS, BRAF, PIK3CA, TP53)

### 3. In Vitro vs In Vivo

- DepMap uses cell lines, not patient tumors
- Dr. Spinetti's observation may be patient-specific
- **Next step**: Validate experimentally in patient-derived models

---

## RECOMMENDATIONS

### For Therapeutic Development

1. **Primary Lead**: **NRAS √ó CLK4**

   - Target: NRAS-mutant melanoma, AML
   - Biomarker: NRAS hotspot mutations (G12, G13, Q61)
   - Combination: Consider with MEK inhibitors

2. **Secondary Leads**: **EGFR patterns** (if more data available)

   - EGFR √ó STK17A, EGFR √ó TBK1
   - Need larger sample sizes to confirm

3. **Deprioritize**: **KRAS √ó STK17A** (unless refined by allele/cancer type)

### For Experimental Validation

1. Test NRAS-mutant cell lines for CLK4 dependency
2. Compare IC50 data from Dr. Taylor's UMF-814L compound
3. Validate in patient-derived xenografts (PDX) if available

---

## ‚úÖ ANALYSIS STATUS

| Component                    | Status                                 |
| ---------------------------- | -------------------------------------- |
| Data Loading                 | ‚úÖ Complete                            |
| Index Alignment Bug          | ‚úÖ Fixed                               |
| Threshold Adjustment         | ‚úÖ Applied                             |
| Synthetic Lethality Analysis | ‚úÖ Complete (44 combinations)          |
| Dr. Spinetti Validation      | ‚úÖ Complete (hypothesis not supported) |
| Results Documentation        | ‚úÖ Complete                            |
| Next Steps Identified        | ‚úÖ Ready                               |

---

## üìû QUESTIONS FOR STAKEHOLDERS

**Dr. Spinetti:**

- Are you surprised by the KRAS √ó STK17A result?
- Interest in NRAS √ó CLK4 for melanoma?
- Should we test KRAS by specific allele?

**Dr. Taylor:**

- Do you have NRAS-mutant cell lines available?
- Can we test CLK4 inhibition with UMF-814L?
- Interest in EGFR patterns for lung/glioblastoma?

**Team:**

- Proceed with Expression Correlation Analysis (Prompt 2)?
- Upload synthetic lethality results to Xata database?
- Schedule review meeting to discuss findings?

---

## üîó RELATED DOCUMENTS

- **Detailed Report**: `SYNTHETIC_LETHALITY_ANALYSIS_RESULTS.md` ‚Üê START HERE
- **Comprehensive Project Report**: `COMPREHENSIVE_ANALYSIS_REPORT.md`
- **Notebook**: `notebooks/04_mutation_context_analysis.ipynb`
- **Data**: `data/processed/synthetic_lethality_results.csv`

---

**Bottom Line**: We found **1 significant synthetic lethality pattern** (NRAS √ó CLK4), but **Dr. Spinetti's specific hypothesis** (KRAS √ó STK17A in lung cancer) **was not validated**. Ready to proceed with next analysis phases.

---

_For full details, see: SYNTHETIC_LETHALITY_ANALYSIS_RESULTS.md_
